Kimberly-Clark Q3 beats estimates, sets 2026 guidance amid Kenvue integration

Kimberly-Clark reported third-quarter adjusted earnings per share of $1.70 on Thursday, surpassing the analyst consensus of $1.66. The stock rose roughly 1.5 percent in trading as investors rotated funds from technology stocks into defensive consumer staples. The results marked a recovery for the maker of Huggies and Kleenex following a sharp decline in September after an earlier investor update.

Revenue for the quarter stood at $4.13 billion, a 0.4 percent decrease from the same period last year. This figure aligned with the LSEG forecast. The company’s performance demonstrated stability in a volatile market environment, with the share price gaining ground as capital flowed into companies with predictable cash flows.

Management emphasized the strategic value of the recently completed acquisition of Kenvue, the owner of Tylenol and Band-Aid. CEO Michael Hsu stated that the merger provides Kimberly-Clark with a stronger foothold in Europe and India, complementing its existing dominance in Mexico and Korea. He noted that Tylenol sales have grown at a mid-to-low single-digit rate since a controversy last year, while Rogaine sales increased by 30 percent year to date. Hsu suggested that the rise in hair-loss medication sales may be linked to the side effects of GLP-1 weight-loss drugs.

Despite the positive momentum, the integration of Kenvue remains an ongoing process. Hsu identified the skin care and oral care segments, which include Neutrogena and Listerine, as areas needing further strategic attention. The company plans to address these categories through marketing adjustments and product assortment resets. More detailed information on these strategies is expected at the CAGNY conference in February.

The company also addressed the impact of the Chinese social media controversy. Organic net sales fell by 1.3 percent in the quarter, with 2.7 percentage points of that decline attributed to the issue in China. Although the Chinese government refuted claims in October that Huggies diapers contained the toxic chemical formamide, consumer confidence is rebuilding slowly. CFO Nelson Urdaneta stated that the China business will remain subdued in the fourth quarter due to the timing of the refutation, but the company is committed to restoring its market leadership, which had held the number one share for five consecutive years prior to the disruption.

For the full year 2026, Kimberly-Clark reaffirmed its outlook for the standalone business. The company guides for organic sales growth of approximately 0.7 percent, which is 100 basis points below the weighted average category growth rate. Adjusted operating profit is expected to rise by a mid-single-digit percentage on a constant currency basis. Adjusted earnings per share are projected to decline by a low-single-digit rate.

The company anticipates that the Kenvue integration will result in mid-single-digit earnings dilution for 2027. This projection accounts for the shares issued in the cash and stock acquisition deal. Management expects double-digit earnings growth by 2028 as the benefits of the combined company are fully realized. More historical pro-forma financial data for the merged entity is expected to be released by mid-February.